Format

Send to

Choose Destination
See comment in PubMed Commons below
Nucl Med Biol. 2003 Nov;30(8):861-8.

Gastrin releasing peptide (GRP) receptor targeted radiopharmaceuticals: a concise update.

Author information

  • 1Radiopharmaceutical Sciences Institute, University of Missouri, Columbia, MO 65211, USA.

Abstract

The gastrin releasing peptide (GRP) receptor is becoming an increasingly attractive target for development of new radiolabeled peptides with diagnostic and therapeutic potential. The attractiveness of the GRP receptor as a target is based upon the functional expression of GRP receptors in several tumors of neuroendocrine origin including prostate, breast, and small cell lung cancer. This concise review outlines some of the efforts currently underway to develop new GRP receptor specific radiopharmaceuticals by employing a variety of radiometal chelation systems.

PMID:
14698790
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk